Criteria to qualify for study: Drug used in study:
  • Relapsed of refractory AML; previously untreated AML not suitable for intensive Induction.

HR 41

A Phase 1/2, Open label, Mulitcenter 2 part study to access the safety, tolerability, Pharmaconetics, and efficacy, of AZD2811 Nanoparticle as Monotherapy or in combination in treatment – naïve or relapsed/refractory Acute Myeloid Leukemia.

Criteria to qualify for study: Drug used in study:
  • Newly diagnosed AML not previously treated or AML in remission after induction.

AML 47

A phase lb/ll Study evaluating the safety and efficacy of idasanutlin in combination with Cytarabine and Daunorubicin in patients newly diagnosed with Acute Myeloid leukemia (AML) and the safety and efficacy of Idasanutlin in the maintenance of first AML complete remission.

Criteria to qualify for study: Drug used in study:
  • Newly diagnosed AML, including MDS-transformed or treatment related.

AML 51

A phase 1 multi-dose study of human placental hematopoietic stem cell derived natural killer cells (CYNK-001) in adults with newly diagnosed primary of secondary acute myeloid leukemia (AML) in morphologic complete remission with minimal residual disease (MRD).

Criteria to qualify for study: Drug used in study:
  • High risk AML or MDS; ECOG 0 or 1

BMT 30

Graft-Versus-Tumor Augmentation with Nivolumab for High-Risk patients with MDS and AML after Allogeneic Stem Cell Transplantation using post-transplant Cyclophophamide.